Table 2.
Cost and potential benefits of palliative cancer treatments in Norfolk and Norwich University Hospital Trust
| Treatment | No of patients given treatment | Drug cost (£000) | Proved benefit | Cost per quality adjusted life year gained (£000) |
|---|---|---|---|---|
| Second line docetaxel for lung cancer | 15 | 45 | Median survival improved by 2 months | 17.55w8 |
| Taxanes for breast cancer | 35 | 150 | Median time to progression improved by 5-16 weeks | 19w9 |
| Temozolomide for glioma | 18 | 100 | Median survival increased by 6 weeks | 35w10 |
| Paclitaxel for ovarian cancer | 50 | 100 | Median survival improved by 0-14 months | 7-45w11 |
| Irinotecan and oxaliplatin, first line treatment for colorectal cancer | 45 | 300 | Median survival increased by 2-3 months | Irinotecan 30-58, oxaliplatin 23-57 per progression-free life yearw12 |
| Herceptin for breast cancer | 15 | 250 | Median time to progression improved by 4 months | 37.5 per quality adjusted life year in combination regimen, 7.5 per life year as single agentw13 |
| Gemcitabine for pancreatic cancer | 30 | 55 | Median survival improved by 6 weeks | 7-18w14 |
| Total | 208 | 997 |